Overview

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the digestive tract, and unlike carcinomas it is defined less by its site of origin than by its driving molecular alteration. The large majority of GISTs are powered by activating mutations in just two receptor tyrosine kinase genes: KIT and PDGFRA. A focused two-gene test that reads both KIT and PDGFRA therefore sits at the center of how these tumors are classified, prognosed, and matched to therapy. Understanding the biology behind the test is the first step toward using its result well.

Receptor Tyrosine Kinases as Oncogenic Drivers

KIT (also called CD117) and PDGFRA encode closely related receptor tyrosine kinases that normally sit on the cell surface and switch on only when their ligand binds. In GIST, a single activating mutation locks the kinase domain into a permanently active conformation. This constitutive signaling feeds directly into the PI3K-AKT and RAS-MAPK cascades, two of the principal highways that tell a cell to survive, grow, and divide. Because the mutation, not an external growth signal, is the engine of the tumor, blocking that kinase is a rational and effective therapeutic strategy.

How Mutation Detection Directs Therapy

Imatinib, a small-molecule inhibitor of KIT and PDGFRA kinases, is the standard first-line therapy for advanced GIST, and most KIT mutations render the tumor sensitive to it. The picture is more nuanced for PDGFRA: the D842V substitution in PDGFRA is inherently resistant to imatinib, yet it is exquisitely sensitive to avapritinib, a newer agent designed for exactly that pocket. A two-gene report therefore does more than confirm a diagnosis; it steers the clinician toward the agent most likely to work and away from one that will not.

What the Two-Gene Panel Delivers

A combined KIT and PDGFRA assessment typically captures the exon 11 and exon 9 hotspots of KIT together with the key PDGFRA exons, reporting each variant with its codon and predicted effect. Cases that are wild-type for both genes, a small but real subgroup, prompt a search for alternative drivers such as SDH defects or NF1 alteration. For the laboratory and procurement buyer, the value of the panel lies in its simplicity: two genes, a clear report, and an immediate link to an approved targeted option.

FAQ

Q: Which two genes does this GIST test examine? A: It assesses KIT and PDGFRA, the two receptor tyrosine kinase genes that carry the activating mutations driving the large majority of gastrointestinal stromal tumors.

Q: Why are KIT and PDGFRA tested together rather than separately? A: They are the primary, mutually exclusive drivers of GIST, so a single combined panel efficiently covers the mutations that determine both diagnosis and the choice between imatinib and a PDGFRA-specific agent such as avapritinib.

Q: Does finding a KIT or PDGFRA mutation guarantee a treatment response? A: Most KIT mutations respond to imatinib, but the PDGFRA D842V mutation does not and instead calls for a different inhibitor; the test result is what separates these scenarios and guides therapy.